Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Omics data integration identifies ELOVL7 and MMD gene regions as novel loci for adalimumab response in patients with Crohn's disease.

Scientific reports - 9 Mar 2021

Gorenjak Mario, Zupin Mateja, Jezernik Gregor, Skok Pavel, Potočnik Uroš

Abstract excerpt

Response to anti-TNF therapy is of pivotal importance in patients with Crohn's disease (CD). Here we integrated our and previously reported PBMC derived transcriptomic and genomic data for identification of biomarkers for discrimination between responders and non-responders to anti-TNF therapy. CD patients, who were naïve with respect to the treatment with biologicals, were enrolled in the study. DNA and RNA were...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adalimumab
Share to Crohn Disease

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Fatty Acid Elongases

Share to Genetic Loci

Share to Genomics

Share to Intracellular Signaling Peptides and Proteins

Share to Introns

Share to Transcriptome

Source

Open in PubMed Open full text

Identifiers

PMID: 33750834
DOI: 10.1038/s41598-021-84909-z
PMCID: PMC7970911

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Omics data integration identifies ELOVL7 and MMD gene regions as novel loci for adalimumab response in patients with Crohn's disease.PMID 33750834Read ↗

Identification of Specific Biomarkers and Pathways in the Treatment Response of Infliximab for Inflammatory Bowel Disease: In-Silico AnalysisSemantic proximity Read ↗

Genomic analysis unlocks the potential of denosumab as a targeted therapy for Crohn's disease.Semantic proximity Read ↗

Mining Transcriptional Data for Precision Medicine: Bioinformatics Insights into Inflammatory Bowel DiseaseSemantic proximity Read ↗

A Combined Transcriptomic and Genomic Analysis Identifies a Gene Signature Associated With the Response to Anti-TNF Therapy in Rheumatoid ArthritisSemantic proximity Read ↗

High-throughput omics technologies in inflammatory bowel diseaseSemantic proximity Read ↗

Integrated cell type-specific analysis of blood and gut identifies matching eQTL for 140 IBD risk loci and entrectinib as possible repurposing candidateSemantic proximity Read ↗

Longitudinal multi-omics analysis identifies early blood-based predictors of anti-TNF therapy response in inflammatory bowel diseaseSemantic proximity Read ↗

Genetic polymorphism in ATG16L1 gene influences the response to adalimumab in Crohn's disease patients.Semantic proximity Read ↗

Development of a Machine Learning Model to Predict Non-Durable Response to Anti-TNF Therapy in Crohn’s Disease Using Transcriptome Imputed from GenotypesSemantic proximity Read ↗

Response to Infliximab in Crohn's Disease: Genetic Analysis Supporting Expression Profile.Semantic proximity Read ↗

High-Throughput Whole-Exome Sequencing and Large-Scale Computational Analysis to Identify the Genetic Biomarkers to Predict the Vedolizumab Response Status in Inflammatory Bowel Disease Patients from Saudi ArabiaSemantic proximity Read ↗

Whole blood DNA methylation changes are associated with anti-TNF drug concentration in patients with Crohn’s diseaseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.